Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023230857> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2023230857 endingPage "622" @default.
- W2023230857 startingPage "622" @default.
- W2023230857 abstract "The licensure of new vaccines in 2001 in Canada means that pneumococcal and group C meningococcal infections can be added to the list of vaccine-preventable diseases. The successful control of these two diseases will require all provincial and territorial governments in Canada to add the new vaccines to their routine immunization programs.Streptococcus pneumoniae is the most common cause of bacterial infections in children. During the past 50 years, approximately 500,000 cases of pneumococcal disease and 200 to 400 cases of meningococcal disease have occurred annually in Canada. Although all age groups are affected, the peak for both bacteria incidence is in infants younger than two years of age.The new vaccines consist of either seven pneumococcal polysaccharides or the group C meningococcal polysaccharide covalently bound to a carrier protein. Both vaccines are very safe. Local reactions occur in 10% to 20% of recipients, but are mild and last only one to two days. Fever, irritability and other general adverse events are not increased in frequency or severity by giving either of these conjugate vaccines at the same time as diphtheria-tetanus-acellular pertussis or diphtheria-tetanus-acellular pertussis-inactivated-Haemophilus influenzae type b vaccine.The pneumococcal and meningococcal conjugate vaccines are highly immunogenic at all ages, including infancy. More importantly, the vaccines also induce immune memory so that protection is expected to last many years, if not for life.The pneumococcal conjugate vaccine is 97% effective in preventing bacteremia and meningitis. The meningococcal conjugate vaccine is also very effective. Within nine months of starting routine vaccination in England and Wales, the frequency of group C disease decreased by 97% in vaccinated adolescents and by 92% in infants and toddlers.The lack of an effective vaccine against group B meningococci is an important defect in the control of meningococcal disease. When an effective vaccine is developed against group B strains, bacterial meningitis in children may join diphtheria, tetanus, H influenzae type b and polio as diseases of the past." @default.
- W2023230857 created "2016-06-24" @default.
- W2023230857 creator A5051617536 @default.
- W2023230857 date "2002-11-01" @default.
- W2023230857 modified "2023-10-14" @default.
- W2023230857 title "Meningococcal and pneumococcal disease" @default.
- W2023230857 doi "https://doi.org/10.1093/pch/7.9.622" @default.
- W2023230857 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2796519" @default.
- W2023230857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20046441" @default.
- W2023230857 hasPublicationYear "2002" @default.
- W2023230857 type Work @default.
- W2023230857 sameAs 2023230857 @default.
- W2023230857 citedByCount "2" @default.
- W2023230857 countsByYear W20232308572020 @default.
- W2023230857 countsByYear W20232308572023 @default.
- W2023230857 crossrefType "journal-article" @default.
- W2023230857 hasAuthorship W2023230857A5051617536 @default.
- W2023230857 hasBestOaLocation W20232308571 @default.
- W2023230857 hasConcept C126322002 @default.
- W2023230857 hasConcept C177713679 @default.
- W2023230857 hasConcept C187212893 @default.
- W2023230857 hasConcept C2776645655 @default.
- W2023230857 hasConcept C2778458888 @default.
- W2023230857 hasConcept C2779134260 @default.
- W2023230857 hasConcept C2781253189 @default.
- W2023230857 hasConcept C3020803494 @default.
- W2023230857 hasConcept C501593827 @default.
- W2023230857 hasConcept C523546767 @default.
- W2023230857 hasConcept C54355233 @default.
- W2023230857 hasConcept C71924100 @default.
- W2023230857 hasConcept C86803240 @default.
- W2023230857 hasConcept C89423630 @default.
- W2023230857 hasConceptScore W2023230857C126322002 @default.
- W2023230857 hasConceptScore W2023230857C177713679 @default.
- W2023230857 hasConceptScore W2023230857C187212893 @default.
- W2023230857 hasConceptScore W2023230857C2776645655 @default.
- W2023230857 hasConceptScore W2023230857C2778458888 @default.
- W2023230857 hasConceptScore W2023230857C2779134260 @default.
- W2023230857 hasConceptScore W2023230857C2781253189 @default.
- W2023230857 hasConceptScore W2023230857C3020803494 @default.
- W2023230857 hasConceptScore W2023230857C501593827 @default.
- W2023230857 hasConceptScore W2023230857C523546767 @default.
- W2023230857 hasConceptScore W2023230857C54355233 @default.
- W2023230857 hasConceptScore W2023230857C71924100 @default.
- W2023230857 hasConceptScore W2023230857C86803240 @default.
- W2023230857 hasConceptScore W2023230857C89423630 @default.
- W2023230857 hasIssue "9" @default.
- W2023230857 hasLocation W20232308571 @default.
- W2023230857 hasLocation W20232308572 @default.
- W2023230857 hasLocation W20232308573 @default.
- W2023230857 hasLocation W20232308574 @default.
- W2023230857 hasOpenAccess W2023230857 @default.
- W2023230857 hasPrimaryLocation W20232308571 @default.
- W2023230857 hasRelatedWork W1968337279 @default.
- W2023230857 hasRelatedWork W1971642193 @default.
- W2023230857 hasRelatedWork W2014533558 @default.
- W2023230857 hasRelatedWork W2020311917 @default.
- W2023230857 hasRelatedWork W2395902861 @default.
- W2023230857 hasRelatedWork W2418962079 @default.
- W2023230857 hasRelatedWork W2761246466 @default.
- W2023230857 hasRelatedWork W2917801510 @default.
- W2023230857 hasRelatedWork W2989996002 @default.
- W2023230857 hasRelatedWork W2187038584 @default.
- W2023230857 hasVolume "7" @default.
- W2023230857 isParatext "false" @default.
- W2023230857 isRetracted "false" @default.
- W2023230857 magId "2023230857" @default.
- W2023230857 workType "article" @default.